{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:02:39Z","timestamp":1759230159941},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00280-010-1457-z","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T06:45:38Z","timestamp":1284965138000},"page":"723-728","source":"Crossref","is-referenced-by-count":10,"title":["Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization"],"prefix":"10.1007","volume":"67","author":[{"given":"Emiliano S.","family":"Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manglio M.","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Oscar","family":"Croxatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Mazzolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan E.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:7070","journal-title":"Nature"},{"key":"1457_CR2","doi-asserted-by":"crossref","unstructured":"Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ (2008) Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 86(12):1720\u20131724","DOI":"10.1097\/TP.0b013e3181903b0a"},{"key":"1457_CR3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"R Manzano","year":"2007","unstructured":"Manzano R, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Ch\u00e9vez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by Bevacizumab (Avastin). Br J Ophthalmol 91:804\u2013807","journal-title":"Br J Ophthalmol"},{"key":"1457_CR4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefe\u2019s Arch Clin Exp Ophthalmol 245:1577\u20131579","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"1457_CR5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ejso.2009.01.014","volume":"35","author":"R Greil","year":"2009","unstructured":"Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B (2009) Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2\/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study. Eur J Surg Oncol 35:1048\u20131054","journal-title":"Eur J Surg Oncol"},{"key":"1457_CR6","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","volume":"113","author":"AA Moshfeghi","year":"2006","unstructured":"Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002\u20132011","journal-title":"Ophthalmology"},{"key":"1457_CR7","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","volume":"168","author":"N Jo","year":"2006","unstructured":"Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036\u20132053","journal-title":"Am J Pathol"},{"key":"1457_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02713680701885470","volume":"33","author":"S Sarman","year":"2008","unstructured":"Sarman S, Mancini J, van der Ploeg I, Croxatto JO, Kvanta A, Gallo JE (2008) Involvement of purinergic p2 receptors in experimental retinal neovascularization. Curr Eye Res 33:285\u2013291","journal-title":"Curr Eye Res"},{"key":"1457_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(94)00048-4","volume":"64","author":"MP Abbracchio","year":"1994","unstructured":"Abbracchio MP, Burnstock G (1994) Purinuceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64:445\u2013475","journal-title":"Pharmacol Ther"},{"key":"1457_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002800050885","volume":"43","author":"G Bocci","year":"1999","unstructured":"Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, Del Tacca M (1999) Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 43:205\u2013212","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"1457_CR11","first-page":"2239","volume":"53","author":"CA Stein","year":"1993","unstructured":"Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53(Suppl):2239\u20132248","journal-title":"Cancer Res"},{"key":"1457_CR12","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1006\/jmcc.1996.0142","volume":"28","author":"J Waltenberger","year":"1996","unstructured":"Waltenberger J, Mayr U, Frank H, Hombach V (1996) Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28:1523\u20131529","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"1457_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/ICO.0b013e3181ae91e3","volume":"29","author":"HS Lee","year":"2010","unstructured":"Lee HS, Chung SK (2010) The effect of subconjunctival suramin on corneal neovascularization in rabbits. Cornea 29(1):86\u201392","journal-title":"Cornea"},{"key":"1457_CR14","unstructured":"Lopez ES Croxatto JO, Kvanta A, and Gallo JE(2007). Effect of Bevacizumab (Avastin) and Suramin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 48: E-Abstract 1717"},{"key":"1457_CR20","first-page":"2148","volume":"30","author":"LD Ormerod","year":"1989","unstructured":"Ormerod LD, Abelson MB, Kenyon KR (1989) Standard models of corneal injury using Alcali-Inmersed filter discs. Invest Ophthalmol Vis Sci 30:2148\u20132153","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1457_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"JH Chang","year":"2001","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242\u2013249","journal-title":"Curr Opin Ophthalmol"},{"key":"1457_CR16","doi-asserted-by":"crossref","unstructured":"Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S (2010) Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 24(5):816\u2013824","DOI":"10.1038\/eye.2009.219"},{"key":"1457_CR17","doi-asserted-by":"crossref","unstructured":"Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL(2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study 19:1903\u20131909","DOI":"10.1093\/annonc\/mdn412"},{"key":"1457_CR18","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jcrs.2007.07.020","volume":"33","author":"F Luengo Gimeno","year":"2007","unstructured":"Luengo Gimeno F, Lavigne V, Gatto S, Croxatto JO, Correa L, Gallo JE (2007) Advances in corneal stem-cell transplantation in rabbits with severe ocular alkali burns. J Cataract Refract Surg 33:1958\u20131965","journal-title":"J Cataract Refract Surg"},{"key":"1457_CR19","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI116816","volume":"92","author":"G Strassman","year":"1993","unstructured":"Strassman G, Fong M, Freter CE, Windsor S, D`Alessandro F, Nordan RP (1993) Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92:2152\u20132159","journal-title":"J Clin Invest"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1457-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1457-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1457-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:39:36Z","timestamp":1559687976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1457-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1457-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]}}}